{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:19:28Z","timestamp":1793747968757,"version":"4.6.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02664-7","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:15:48Z","timestamp":1749082548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Recent developments in the research of Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, diagnosis and treatment"],"prefix":"10.1186","volume":"30","author":[{"given":"Li-min","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ning","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"6","key":"2664_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archpedi.1922.04120120077005","volume":"24","author":"AM Stevens","year":"1922","unstructured":"Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child. 1922;24(6):526\u201333. https:\/\/doi.org\/10.1001\/archpedi.1922.04120120077005.","journal-title":"Am J Dis Child"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","volume":"68","author":"A Lyell","year":"1956","unstructured":"Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:335\u201361. https:\/\/doi.org\/10.1111\/j.1365-2133.1956.tb12766.x.","journal-title":"Br J Dermatol"},{"key":"2664_CR3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24748.1","author":"A Hasegawa","year":"2024","unstructured":"Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. FResearch. 2024. https:\/\/doi.org\/10.12688\/f1000research.24748.1.","journal-title":"FResearch."},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92.","journal-title":"Arch Dermatol"},{"issue":"1","key":"2664_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, Phillips EJ, Chung WH. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10(1):30. https:\/\/doi.org\/10.1038\/s41572-024-00514-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2664_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"M Lerch","year":"2018","unstructured":"Lerch M, Mainetti C, Beretta-Piccoli BT, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147\u201376. https:\/\/doi.org\/10.1007\/s12016-017-8654-z.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/ACI.0000000000000914","volume":"23","author":"S Yuki","year":"2023","unstructured":"Yuki S, Riichiro A. New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol. 2023;23:271\u20138. https:\/\/doi.org\/10.1097\/ACI.0000000000000914.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2664_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.031","author":"N Frey","year":"2017","unstructured":"Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Investig Dermatol. 2017. https:\/\/doi.org\/10.1016\/j.jid.2017.01.031.","journal-title":"J Investig Dermatol"},{"key":"2664_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2019.10.008","author":"L Yang","year":"2019","unstructured":"Yang L, Shou Y-H, et al. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns. 2019. https:\/\/doi.org\/10.1016\/j.burns.2019.10.008.","journal-title":"Burns"},{"issue":"8","key":"2664_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40629-019-00111-8","volume":"28","author":"M Paulmann","year":"2019","unstructured":"Paulmann M, Mockenhaupt M. Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo J Int. 2019;28(8):311\u201326. https:\/\/doi.org\/10.1007\/s40629-019-00111-8.","journal-title":"Allergo J Int"},{"issue":"11","key":"2664_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","volume":"129","author":"MA Miliszewski","year":"2016","unstructured":"Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221.","journal-title":"Am J Med"},{"key":"2664_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/iraa082","author":"RM Nygaard","year":"2020","unstructured":"Nygaard RM, Endorf FW. Differences in treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis at burn centers and nonburn centers. J Burn Care Res. 2020. https:\/\/doi.org\/10.1093\/jbcr\/iraa082.","journal-title":"J Burn Care Res"},{"issue":"4","key":"2664_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/08820538.2021.1893764","volume":"36","author":"VK Neerukonda","year":"2021","unstructured":"Neerukonda VK, Stagner AM. Stevens johnson syndrome: a review of a vision and life- threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors. Semin Ophthalmol. 2021;36(4):270\u201381. https:\/\/doi.org\/10.1080\/08820538.2021.1893764.","journal-title":"Semin Ophthalmol"},{"key":"2664_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178253","volume":"23","author":"PN Shah","year":"2024","unstructured":"Shah PN, Romar GA, Manukyan A, Ko WC, Hsieh PC, Velasquez GA, Schunkert EM, Fu X, Guleria I, Bronson RT, Wei K, Waldman AH, Vleugels FR, Liang MG, Giobbie-Hurder A, Mostaghimi A, Schmidt BA, Barrera V, Foreman RK, Garber M, Divito SJ. Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets. J Clin Invest. 2024;23: e178253. https:\/\/doi.org\/10.1172\/JCI178253.","journal-title":"J Clin Invest"},{"issue":"6","key":"2664_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bjps.2016.04.016","volume":"69","author":"P Wolkenstein","year":"2016","unstructured":"Wolkenstein P, Wilson YT. Toxic epidermal necrolysis: the past, the guidelines and challenges for the future. J Plast Reconstr Aesthet Surg. 2016;69(6):733\u20135. https:\/\/doi.org\/10.1016\/j.bjps.2016.04.016.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"12","key":"2664_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343\u201350. https:\/\/doi.org\/10.1038\/nm.1884.","journal-title":"Nat Med"},{"issue":"8040","key":"2664_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","volume":"635","author":"TM Nordmann","year":"2024","unstructured":"Nordmann TM, Anderton H, Hasegawa A, Schweizer L, Zhang P, Stadler PC, Sinha A, Metousis A, Rosenberger FA, Zwiebel M, Satoh TK, Anzengruber F, Strauss MT, Tanzer MC, Saito Y, Gong T, Thielert M, Kimura H, Silke N, Rodriguez EH, Restivo G, Nguyen HH, Gross A, Feldmeyer L, Joerg L, Levesque MP, Murray PJ, Ingen-Housz-Oro S, Mund A, Abe R, Silke J, Ji C, French LE, Mann M. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. Nature. 2024;635(8040):1001\u20139. https:\/\/doi.org\/10.1038\/s41586-024-08061-0.","journal-title":"Nature"},{"issue":"6","key":"2664_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ajd.14329","volume":"65","author":"TJ Stewart","year":"2024","unstructured":"Stewart TJ, Farrell J, Frew JW. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 2024;65(6):491\u2013504. https:\/\/doi.org\/10.1111\/ajd.14329.","journal-title":"Australas J Dermatol"},{"key":"2664_CR19","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2017-0103","author":"R Yuliwulandari","year":"2017","unstructured":"Yuliwulandari R, Kristin E, Prayuni K, et al. Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics. 2017. https:\/\/doi.org\/10.2217\/pgs-2017-0103.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"2664_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41439-019-0082-6","volume":"28","author":"M Ueta","year":"2019","unstructured":"Ueta M, Nakamura R, Saito Y, Tokunaga K, Sotozono C, Yabe T, Aihara M, Matsunaga K, Kinoshita S. Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. Hum Genome Var. 2019;28(6):50. https:\/\/doi.org\/10.1038\/s41439-019-0082-6.","journal-title":"Hum Genome Var"},{"key":"2664_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043650","author":"M Ueta","year":"2012","unstructured":"Ueta M, Tokunaga K, Sotozono C, et al. HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0043650.","journal-title":"PLoS ONE"},{"issue":"1","key":"2664_CR22","doi-asserted-by":"publisher","first-page":"16240","DOI":"10.1038\/s41598-019-52619-2","volume":"9","author":"K Nakatani","year":"2019","unstructured":"Nakatani K, Ueta M, Khor SS, et al. Identification of HLA-A* 02: 06: 01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. Sci Rep. 2019;9(1):16240.","journal-title":"Sci Rep"},{"key":"2664_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311823","author":"P Jongkhajornpong","year":"2018","unstructured":"Jongkhajornpong P, Lekhanont K, Pisuchpen P, et al. Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. Br J Ophthalmol. 2018. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311823.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2664_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1248\/yakushi.14-00249-3","volume":"135","author":"Y Saito","year":"2015","unstructured":"Saito Y, Kodama S, Sugiyama E, et al. Predictive genomic markers for severe adverse drug reactions. Yakugaku Zasshi J Pharma Soc Jpn. 2015;135(4):589\u201395. https:\/\/doi.org\/10.1248\/yakushi.14-00249-3.","journal-title":"Yakugaku Zasshi J Pharma Soc Jpn"},{"key":"2664_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.05.015","author":"Q Wang","year":"2017","unstructured":"Wang Q, Sun S, Xie M, et al. Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis. Epilepsy Res. 2017. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.05.015.","journal-title":"Epilepsy Res"},{"key":"2664_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.886377","volume":"13","author":"CW Wang","year":"2022","unstructured":"Wang CW, Preclaro IAC, Lin WH, et al. An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice. Front Pharmacol. 2022;13: 886377. https:\/\/doi.org\/10.3389\/fphar.2022.886377.","journal-title":"Front Pharmacol"},{"key":"2664_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1946514","author":"T Jantararoungtong","year":"2021","unstructured":"Jantararoungtong T, Tempark T, Koomdee N, et al. Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art. Expert Opinion Drug Metab Toxicol. 2021. https:\/\/doi.org\/10.1080\/17425255.2021.1946514.","journal-title":"Expert Opinion Drug Metab Toxicol"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"K Vivek","year":"2017","unstructured":"Vivek K, Neha C, Mohit G, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. https:\/\/doi.org\/10.3389\/fphar.2017.00049.","journal-title":"Front Pharmacol"},{"key":"2664_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","volume":"456","author":"A Teufel","year":"2019","unstructured":"Teufel A, Zhan T, H\u00e4rtel N, Bornschein J, Ebert MP, Schulte N. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Lett. 2019;456:80.","journal-title":"Cancer Lett"},{"key":"2664_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"W Peng-Fei","year":"2017","unstructured":"Peng-Fei W, Yang C, Si-Ying S, et al. Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. https:\/\/doi.org\/10.3389\/fphar.2017.00730.","journal-title":"Front Pharmacol"},{"key":"2664_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","author":"SR Ellis","year":"2020","unstructured":"Ellis SR, Vierra AT, Millsop JW, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.105.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2664_CR32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor\u2013related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"key":"2664_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015. https:\/\/doi.org\/10.1093\/annonc\/mdv383.","journal-title":"Ann Oncol"},{"key":"2664_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4103\/2311-8571.353662","volume":"9","author":"LM Yang","year":"2023","unstructured":"Yang LM, Zhou WM, Guo QR, et al. Brusatol inhibits proliferation, migration, and invasion of nonsmall cell lung cancer PC-9 cells. World J Tradit Chin Med. 2023;9:454\u201360.","journal-title":"World J Tradit Chin Med"},{"key":"2664_CR35","doi-asserted-by":"publisher","DOI":"10.5070\/D3273052777","author":"T Gracia-Cazaa","year":"2021","unstructured":"Gracia-Cazaa T, Padgett E, Ver\u00f3nica C, et al. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer. Dermatol J. 2021. https:\/\/doi.org\/10.5070\/D3273052777.","journal-title":"Dermatol J"},{"key":"2664_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000302","author":"IT Logan","year":"2020","unstructured":"Logan IT, Zaman S, Hussein L, et al. Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: a case report and literature review. J Immunother. 2020. https:\/\/doi.org\/10.1097\/CJI.0000000000000302.","journal-title":"J Immunother"},{"key":"2664_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620914796","author":"I Riano","year":"2020","unstructured":"Riano I, Cristancho C, Treadwell T. Stevens-Johnson syndrome-like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer. J Investig Med High Impact Case Reports. 2020. https:\/\/doi.org\/10.1177\/2324709620914796.","journal-title":"J Investig Med High Impact Case Reports"},{"key":"2664_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.804212","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Fu R, Jiang T, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022;12: 804212. https:\/\/doi.org\/10.3389\/fonc.2022.804212.","journal-title":"Front Oncol"},{"issue":"9","key":"2664_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.898790","volume":"13","author":"AM Kuo","year":"2022","unstructured":"Kuo AM, Markova A. High grade dermatologic adverse events associated with immune checkpoint blockade for cancer. Front Med (Lausanne). 2022;13(9): 898790. https:\/\/doi.org\/10.3389\/fmed.2022.898790.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"2664_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","volume":"4","author":"LL Griffin","year":"2018","unstructured":"Griffin LL, Cove-Smith L, Alachkar H, et al. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Reports. 2018;4(3):229\u201331. https:\/\/doi.org\/10.1016\/j.jdcr.2017.09.028.","journal-title":"JAAD Case Reports"},{"key":"2664_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001162","author":"W Kian","year":"2021","unstructured":"Kian W, Zemel M, Elobra F, et al. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2021. https:\/\/doi.org\/10.1097\/CAD.0000000000001162.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"2664_CR42","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/all.12410","volume":"69","author":"T Ishida","year":"2014","unstructured":"Ishida T, Kano Y, Mizukawa Y, et al. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy. 2014;69(6):798\u2013805. https:\/\/doi.org\/10.1111\/all.12410.","journal-title":"Allergy"},{"issue":"4","key":"2664_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1542\/peds.2010-3322","volume":"128","author":"Y Finkelstein","year":"2011","unstructured":"Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723\u20138. https:\/\/doi.org\/10.1542\/peds.2010-3322.","journal-title":"Pediatrics"},{"key":"2664_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piw085","author":"D Olson","year":"2017","unstructured":"Olson D, Abbott J, Lin C, et al. Characterization of children with recurrent episodes of Stevens Johnson syndrome. J Pediatric Infect Dis Soc. 2017. https:\/\/doi.org\/10.1093\/jpids\/piw085.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2664_CR45","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_510_21","author":"S Aulakh","year":"2022","unstructured":"Aulakh S, Arora R, Sarangal R, et al. Increased predisposition of sjs ten in COVID-19 patients, presenting as post COVID complication: report of two cases. Indian Dermatol Online J. 2022. https:\/\/doi.org\/10.4103\/idoj.idoj_510_21.","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"2664_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.12809\/hkmj166186","volume":"23","author":"QU Lee","year":"2017","unstructured":"Lee QU. Hypersensitivity to antipyretics: pathogenesis, diagnosis, and management. Hong Kong Med J. 2017;23(4):395\u2013403. https:\/\/doi.org\/10.12809\/hkmj166186.","journal-title":"Hong Kong Med J"},{"issue":"8","key":"2664_CR47","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1016\/j.jaip.2019.05.002","volume":"7","author":"N Hama","year":"2019","unstructured":"Hama N, Nishimura K, Hasegawa A, et al. Galectin-7 as a potential biomarker of Stevens-Johnson syndrome\/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. J Allergy Clin Immunol. 2019;7(8):2894\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2019.05.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2664_CR48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jaip.2020.01.006","volume":"8","author":"A Hasegawa","year":"2020","unstructured":"Hasegawa A, Shinkuma S, Hayashi R, et al. RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2020;8(5):1768\u201371. https:\/\/doi.org\/10.1016\/j.jaip.2020.01.006.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2664_CR49","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jaip.2020.09.048","volume":"9","author":"CB Chen","year":"2021","unstructured":"Chen CB, Kuo KL, Wang CW, et al. Taiwan Severe Cutaneous Adverse Reaction Consortium. Detecting lesional granulysin levels for rapid diagnosis of cytotoxic T lymphocyte-mediated bullous skin disorders. J Allergy Clin Immunol Pract. 2021;9(3):1327\u201337. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.048.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2664_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","volume":"8","author":"F Wang","year":"2018","unstructured":"Wang F, Ye Y, Luo ZY, et al. Diverse expression of TNF-\u03b1 and CCL27 in serum and blister of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Clin Transl Allergy. 2018;8(1):12. https:\/\/doi.org\/10.1186\/s13601-018-0199-6.","journal-title":"Clin Transl Allergy"},{"issue":"8","key":"2664_CR51","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3390\/biomedicines10081868","volume":"10","author":"T Bell\u00f3n","year":"2022","unstructured":"Bell\u00f3n T, Gonz\u00e1lez-Valle O, Sendagorta E, Lerma V, Martinez Del Rio J, Martinez C, Servera G, Gonz\u00e1lez-Herrada C, Cachafeiro L, Lorente JA, Caba\u00f1as R, Herranz P, de Abajo F, PIELenRed Study. IL-15\/IL-15R\u03b1 in SJS\/TEN: relevant expression of IL15 and IL15RA in affected skin. Biomedicines. 2022;10(8):1868. https:\/\/doi.org\/10.3390\/biomedicines10081868.","journal-title":"Biomedicines."},{"issue":"5","key":"2664_CR52","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","volume":"137","author":"SC Su","year":"2017","unstructured":"Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Invest Dermatol. 2017;137(5):1065\u201373. https:\/\/doi.org\/10.1016\/j.jid.2016.11.034.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2664_CR53","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.jaip.2023.06.008","volume":"11","author":"N Rodr\u00edguez-Otero","year":"2023","unstructured":"Rodr\u00edguez-Otero N, Chamorro-P\u00e9rez J, Fern\u00e1ndez-Lozano C, El\u00edas-S\u00e1enz I, Bern\u00e1-Rico E, de Nicol\u00e1s-Ruanes B, Mel\u00e9ndez-Gispert MR, Moreno-Garc\u00eda Del Real C, Mart\u00ednez-Botas J, Cort\u00e9s-Salgado A, Solano-Solares E. Nivolumab-induced Stevens- Johnson syndrome: not only due to PD-1 inhibition. J Allergy Clin Immunol Pract. 2023;11(9):2936\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.06.008.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2664_CR54","doi-asserted-by":"publisher","first-page":"496","DOI":"10.18176\/jiaci.0789","volume":"32","author":"A Carr\u00f3n-Herrero","year":"2022","unstructured":"Carr\u00f3n-Herrero A, Fern\u00e1ndez-Lozano C, Botella-Carretero JI, Palomino-Quintanilla L, Mart\u00ednez-Botas J, Solano-Solares E. Delayed hypersensitivity reaction to iron salts: from diagnosis to desensitization. J Investig Allergol Clin Immunol. 2022;32(6):496\u20138. https:\/\/doi.org\/10.18176\/jiaci.0789.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"2664_CR55","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jaip.2021.12.041","volume":"10","author":"M Giraldo-Tugores","year":"2022","unstructured":"Giraldo-Tugores M, Fern\u00e1ndez-Lozano C, Carr\u00f3n-Herrero A, Gajate P, Martinez-Botas J, Pueyo-L\u00f3pez C, Solano-Solares E, Berges-Gimeno MP. Successful rapid desensitization to atezolizumabin delayed hypersensitivity confirmed with lymphocyte transformation test. J Allergy Clin Immunol Pract. 2022;10(6):1649\u201351. https:\/\/doi.org\/10.1016\/j.jaip.2021.12.041.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2664_CR56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1089\/jir.2019.0012","volume":"40","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu WS, Qin XM. Cytokines\/chemokines: Novel biomarkers associated with severe cutaneous adverse reactions. J Interferon Cytokine Res. 2020;40(4):172\u201381. https:\/\/doi.org\/10.1089\/jir.2019.0012.","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"2664_CR57","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/jdv.14890","volume":"32","author":"N Suthumchai","year":"2018","unstructured":"Suthumchai N, Srinoulprasert Y, Thantiworasit P, et al. The measurement of drug- induced interferon gamma- releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2018;32(6):992\u20138. https:\/\/doi.org\/10.1111\/jdv.14890.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2664_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"2664_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010. https:\/\/doi.org\/10.1038\/clpt.2009.252.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2664_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149\u201353. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00061.x.","journal-title":"J Invest Dermatol"},{"key":"2664_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16137","author":"I Torres-Navarro","year":"2020","unstructured":"Torres-Navarro I, Briz-Red\u00f3n \u00c1, Botella-Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol JEADV. 2020. https:\/\/doi.org\/10.1111\/jdv.16137.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"2664_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12466","author":"S Bansal","year":"2015","unstructured":"Bansal S, Garg VK, Sardana K, Sarkar R. A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis. Int J Dermatol. 2015. https:\/\/doi.org\/10.1111\/ijd.12466.","journal-title":"Int J Dermatol"},{"key":"2664_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0817-2","author":"Y Shou","year":"2021","unstructured":"Shou Y, Yang L, Yang Y, et al. Cohort study of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography. Front Med. 2021. https:\/\/doi.org\/10.1007\/s11684-020-0817-2.","journal-title":"Front Med"},{"issue":"1","key":"2664_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/jbcr\/irae140","volume":"46","author":"NKB Gust","year":"2025","unstructured":"Gust NKB, Adams RM, Frei A, Coughlin M, Klein J, Ridelman E, Shanti C. Utility of the severity-of-illness score for toxic epidermal necrolysis (SCORTEN) in pediatric Stevens-Johnson syndrome patients. J Burn Care Res. 2025;46(1):132\u20137. https:\/\/doi.org\/10.1093\/jbcr\/irae140.","journal-title":"J Burn Care Res"},{"key":"2664_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2017.10.022","author":"P Anthony","year":"2018","unstructured":"Anthony P, Sheena S, et al. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. Burns. 2018. https:\/\/doi.org\/10.1016\/j.burns.2017.10.022.","journal-title":"Burns"},{"issue":"2","key":"2664_CR66","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/idoj.IDOJ_437_20","volume":"12","author":"V Thakur","year":"2021","unstructured":"Thakur V, Vinay K, Kumar S, et al. Factors predicting the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: a 5-year retrospective study. Indian Dermatol Online J. 2021;12(2):258\u201365. https:\/\/doi.org\/10.4103\/idoj.IDOJ_437_20.","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"2664_CR67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","volume":"155","author":"MH Noe","year":"2019","unstructured":"Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson Syndrome\/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155(4):448\u201354. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5605.","journal-title":"JAMA Dermatol"},{"key":"2664_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3654","author":"HK Koh","year":"2020","unstructured":"Koh HK, Fook-Chong S, Lee HY. Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3654.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2664_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","volume":"85","author":"MJ Duplisea","year":"2021","unstructured":"Duplisea MJ, Roberson ML, Chrisco L, Strassle PD, Williams FN, Ziemer CM. Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Am Acad Dermatol. 2021;85(4):873\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.082.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2664_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-024-03327-z","volume":"316","author":"MKM Rayi","year":"2024","unstructured":"Rayi MKM, Monteiro RC, Martis J, et al. Role of neutrophil\u2013lymphocyte ratio as a prognostic marker in SJS\/TEN patients. Arch Dermatol Res. 2024;316(8):1\u20137. https:\/\/doi.org\/10.1007\/s00403-024-03327-z.","journal-title":"Arch Dermatol Res"},{"key":"2664_CR71","doi-asserted-by":"publisher","first-page":"llae332","DOI":"10.1093\/ced\/llae332","volume":"16","author":"WH Han","year":"2024","unstructured":"Han WH, Tshung En Wong T, Yusof RC, Choong RKJ, Yong SS, Faheem NAA, Kwan Z. Prognostic significance of the Systemic Immune-Inflammation Index in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS\/TEN) patients. Clin Exp Dermatol. 2024;16:llae332. https:\/\/doi.org\/10.1093\/ced\/llae332.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"2664_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1067\/mai.2001.118796","volume":"108","author":"A Trautmann","year":"2001","unstructured":"Trautmann A, Akdis M, Schmid-Grendelmeier P, et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol. 2001;108(5):839\u201346. https:\/\/doi.org\/10.1067\/mai.2001.118796.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2664_CR73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000093204","volume":"140","author":"A Kumar","year":"2006","unstructured":"Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol. 2006;140(3):185\u201398. https:\/\/doi.org\/10.1159\/000093204.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"2664_CR74","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","volume":"34","author":"JA Schneider","year":"2017","unstructured":"Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235\u201344. https:\/\/doi.org\/10.1007\/s12325-017-0530-y.","journal-title":"Adv Ther"},{"issue":"2","key":"2664_CR75","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000018112","volume":"198","author":"P Paquet","year":"1999","unstructured":"Paquet P, Pi\u00e9rard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology. 1999;198(2):198\u2013202. https:\/\/doi.org\/10.1159\/000018112.","journal-title":"Dermatology"},{"issue":"10","key":"2664_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D32210032890","volume":"22","author":"P Kumar","year":"2016","unstructured":"Kumar P, Das NK. Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality. Dermatol Online J. 2016;22(10):1. https:\/\/doi.org\/10.5070\/D32210032890.","journal-title":"Dermatol Online J"},{"issue":"1","key":"2664_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","volume":"76","author":"HY Lee","year":"2017","unstructured":"Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.048.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2664_CR78","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","volume":"146","author":"M Fischer","year":"2002","unstructured":"Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146(4):707. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.46833.x.","journal-title":"Br J Dermatol"},{"key":"2664_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00616.x","author":"E Gubinelli","year":"2009","unstructured":"Gubinelli E, Canzona F, Tonanzi T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00616.x.","journal-title":"J Dermatol"},{"issue":"2","key":"2664_CR80","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.dsi.2012.06.005","volume":"31","author":"YY Lee","year":"2013","unstructured":"Lee YY, Ko JH, Wei CH, et al. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatol Sin. 2013;31(2):78\u201381. https:\/\/doi.org\/10.1016\/j.dsi.2012.06.005.","journal-title":"Dermatol Sin"},{"key":"2664_CR81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93349","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Investig. 2018. https:\/\/doi.org\/10.1172\/JCI93349.","journal-title":"J Clin Investig"},{"issue":"5","key":"2664_CR82","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jpag.2021.03.011","volume":"34","author":"M Holtzmph","year":"2024","unstructured":"Holtzmph M, Grimstad F, Cpnp JH, et al. Vulvovaginal involvement in pediatric Stevens-Johnson syndrome: a case series. J Pediatric Adolesc Gynecol. 2024;34(5):745\u20138. https:\/\/doi.org\/10.1016\/j.jpag.2021.03.011.","journal-title":"J Pediatric Adolesc Gynecol"},{"issue":"15","key":"2664_CR83","doi-asserted-by":"publisher","first-page":"1421684","DOI":"10.3389\/fimmu.2024.1421684","volume":"7","author":"CX He","year":"2024","unstructured":"He CX, Guo L, Qu T, Jin HZ. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study. Front Immunol. 2024;7(15):1421684. https:\/\/doi.org\/10.3389\/fimmu.2024.1421684.","journal-title":"Front Immunol"},{"issue":"14","key":"2664_CR84","doi-asserted-by":"publisher","first-page":"1193032","DOI":"10.3389\/fimmu.2023.1193032","volume":"12","author":"R Lotti","year":"2023","unstructured":"Lotti R, Hundt JE, Ludwig RJ, Hammers CM, Bennett B, Amato A, Marconi A, Pincelli C. Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. Front Immunol. 2023;12(14):1193032. https:\/\/doi.org\/10.3389\/fimmu.2023.1193032.","journal-title":"Front Immunol"},{"key":"2664_CR85","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v12i1.4939","author":"M Shekhar","year":"2024","unstructured":"Shekhar M, Iqbal O, Dharan A, El-Khateeb H, Jatavallabhula K, Bu P, Bouchard C. The role of NLRP3 inflammasome in the pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Med Res Arch. 2024. https:\/\/doi.org\/10.18103\/mra.v12i1.4939.","journal-title":"Med Res Arch."},{"key":"2664_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cps.2017.02.006","author":"SJ Hermiz","year":"2017","unstructured":"Hermiz SJ, Diegidio P, Ortiz-Pujols S, et al. Life-threatening skin disorders treated in the burn center: impact of health care-associated infections on length of stay, survival, and hospital charges. Clin Plastic Surg. 2017. https:\/\/doi.org\/10.1016\/j.cps.2017.02.006.","journal-title":"Clin Plastic Surg"},{"issue":"1","key":"2664_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","volume":"89","author":"ND Prost","year":"2010","unstructured":"Prost ND, Ingen-Housz-Oro S, Duong TA, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine. 2010;89(1):28\u201336. https:\/\/doi.org\/10.1097\/MD.0b013e3181ca4290.","journal-title":"Medicine"},{"key":"2664_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2016.1218501","author":"D Monteiro","year":"2016","unstructured":"Monteiro D, Egipto P, Barbosa J, et al. 9 years of a single referral centre management of Stevens\u2014Johnson syndrome and toxic epidermal necrolysis (Lyell\u2019s syndrome). Cutaneous Ocular Toxicol. 2016. https:\/\/doi.org\/10.1080\/15569527.2016.1218501.","journal-title":"Cutaneous Ocular Toxicol"},{"issue":"6","key":"2664_CR89","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000195632","volume":"29","author":"CC Hung","year":"2009","unstructured":"Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633\u20138. https:\/\/doi.org\/10.1159\/000195632.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2664_CR90","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jgh.12849","volume":"30","author":"N Harimoto","year":"2015","unstructured":"Harimoto N, Wang H, Ikegami T, et al. Education and imaging. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol. 2015;30(4):656. https:\/\/doi.org\/10.1111\/jgh.12849.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2664_CR91","doi-asserted-by":"publisher","first-page":"e1194","DOI":"10.1542\/peds.2013-2239","volume":"134","author":"JC White","year":"2014","unstructured":"White JC, Appleman S. Infliximab\/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis. Pediatrics. 2014;134(4):e1194. https:\/\/doi.org\/10.1542\/peds.2013-2239.","journal-title":"Pediatrics"},{"issue":"4","key":"2664_CR92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","volume":"150","author":"ME Morales","year":"2010","unstructured":"Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150(4):505\u201310. https:\/\/doi.org\/10.1016\/j.ajo.2010.04.026.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2664_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12886-017-0464-9","volume":"17","author":"LLW Chow","year":"2024","unstructured":"Chow LLW, Shih KC, Chan JCY, et al. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. BMC Ophthalmol. 2024;17(1):92\u20136. https:\/\/doi.org\/10.1186\/s12886-017-0464-9.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"2664_CR94","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/archdermatol.2009.540","volume":"145","author":"J Gueudry","year":"2009","unstructured":"Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157\u201362. https:\/\/doi.org\/10.1001\/archdermatol.2009.540.","journal-title":"Arch Dermatol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02664-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:15:49Z","timestamp":1749082549000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02664-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}